CD274 and neoplasm: Survival was significantly increased with pembrolizumab compared with the EXTREME regimen for PD-L1 ≥20 CPS (expression on both tumor cells and immune cells in the microenvironment or combined positive score) patients (14.7 vs. 11 months) and PD-L1 ≥1 CPS patients (12.3 vs. 10.4 months) but not in the total population (11.5 vs. 10.7 months).